|5.68||-0.1300||-2.24%||Vol 1.06M||1Y Perf 29.95%|
|Jun 15th, 2021 16:00 DELAYED|
|- -||0.04 0.70%|
|Target Price||8.10||Analyst Rating||Strong Buy 1.00|
|Potential %||42.61||Finscreener Ranking||★★★★★ 68.52|
|Insiders Trans % 3/6/12 mo.||-/-100/33||Value Ranking||★★★★★ 69.57|
|Insiders Value % 3/6/12 mo.||-/-100/68||Growth Ranking||★★★★★ 89.27|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/71||Income Ranking||— -|
|Market Cap||587.11M||Earnings Rating||Buy|
|Price Range Ratio 52W %||93.33||Earnings Date||9th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Aug 2021|
|Estimated EPS Next Report||0.09|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||966.38K|
|Avg. Monthly Volume||1.01M|
|Avg. Quarterly Volume||1.37M|
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 5.68 per share at the end of the most recent trading day (a -2.24% change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 587.11M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 76 people. Catalyst Pharmaceuticals Inc. CEO is Patrick J. McEnany.
The one-year performance of Catalyst Pharmaceuticals Inc. stock is 29.95%, while year-to-date (YTD) performance is 70.06%. CPRX stock has a five-year performance of 628.21%. Its 52-week range is between 2.88 and 5.88, which gives CPRX stock a 52-week price range ratio of 93.33%
Catalyst Pharmaceuticals Inc. currently has a PE ratio of 8.40, a price-to-book (PB) ratio of 3.32, a price-to-sale (PS) ratio of 5.00, a price to cashflow ratio of 14.70, a PEG ratio of 2.32, a ROA of 45.84%, a ROC of 50.96% and a ROE of 51.90%. The company’s profit margin is 60.11%, its EBITDA margin is 34.40%, and its revenue ttm is $120.14 Million , which makes it $1.16 revenue per share.
Of the last four earnings reports from Catalyst Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.09 for the next earnings report. Catalyst Pharmaceuticals Inc.’s next earnings report date is 09th Aug 2021.
The consensus rating of Wall Street analysts for Catalyst Pharmaceuticals Inc. is Strong Buy (1), with a target price of $8.1, which is +42.61% compared to the current price. The earnings rating for Catalyst Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Catalyst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Catalyst Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.16, ATR14 : 0.22, CCI20 : 70.24, Chaikin Money Flow : 0.04, MACD : 0.21, Money Flow Index : 67.45, ROC : 1.79, RSI : 59.43, STOCH (14,3) : 58.33, STOCH RSI : 0.00, UO : 54.86, Williams %R : -41.67), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Catalyst Pharmaceuticals Inc. in the last 12-months were: Alicia Grande (Option Excercise at a value of $0), Brian Elsbernd (Option Excercise at a value of $0), Charles B. O'Keeffe (Buy at a value of $20 930), Charles B. O'Keeffe (Option Excercise at a value of $0), David S. Tierney (Option Excercise at a value of $0), Donald A. Denkhaus (Option Excercise at a value of $0), Gary Ingenito (Option Excercise at a value of $0), Gary Ingenito (Sold 3 668 shares of value $12 644 ), Patrick J. McEnany (Buy at a value of $44 550), Patrick J. McEnany (Option Excercise at a value of $0), Philip H. Coelho (Option Excercise at a value of $0), Richard J. Daly (Option Excercise at a value of $0), Steven R. Miller (Option Excercise at a value of $0)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.